Sentence examples similar to administered a potent from inspiring English sources

Novartis is also pursuing a vaccine consisting of recombinant HCV core protein produced in yeast, administered with a potent T-cell adjuvant immunostimulating complex matrix (IMX) [64].

Here we administered donepezil, a potent acetylcholinesterase inhibitor developed for treating Alzheimer's disease, 15 days before 192-IgG-saporin injection, and thus we examined donepezil effects on neurodegeneration and cognitive deficits.

14, 15 The 24-hour AUC of pitavastatin was increased 4.6-fold when it was concurrently administered with a potent OATP2 inhibitor (eg, cyclosporine), and is thought to be the major rate-limiting step in the hepatobiliary clearance of pitavastatin.

Alternatively, chemicals may be identified as antagonists if they cause statistically significant decreases in the stimulated target tissue weights increase when the chemicals are co-administered with a potent androgen such as testosterone propionate (TP).

Methods To further understand the contribution of thromboxane and to provide novel therapy for PPH, we administered the potent orally active thromboxane synthetase inhibitor and thromboxane receptor antagonist terbogrel for 12 weeks to patients with New York Heart Association functional classification II and III PPH.

Dabigatran should not be administered with potent P-gp inducers [ 11].

Dronedarone also has interactions with other drugs using the CYP system, so should not be administered with potent CYP3A4 inhibitors, including antifungals, certain oral macrolide antibiotics, and protease inhibitors, because CYP3A4 inhibition may increase plasma levels of dronedarone and cause unwanted adverse effects.

Motesanib (AMG 706; Amgen, Thousand Oaks, CA, USA) is an orally administered potent small molecule, which targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and KIT [ 64].

Here, we present AZD0530, a new, orally administered, potent and highly selective dual Src/Abl kinase inhibitor, whose effects have been investigated in solid tumours [ 18].

3 Linagliptin (BI 1356) is a xanthine-based orally administered, potent, and long-acting non-peptidomimetic DPP-4 inhibitor that has been developed for treating T2DM.

Administered early, it is a potent antidote to shame.